Northern Trust Corp Intra Cellular Therapies, Inc. Transaction History

Northern Trust Corp

$586 Billion
Q2 2024

A detailed history of Northern Trust Corp transactions in Intra Cellular Therapies, Inc. stock. As of the latest transaction made, Northern Trust Corp holds 897,954 shares of ITCI stock, worth $65.8 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares

897,954

Previous 877,992 2.27%

Holding current value

$65.8 Million

Previous $60.8 Million 1.22%

% of portfolio

0.01%

Previous 0.01%

29 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	BUY	$64.76 - $79.84 $1.29 Million - $1.59 Million	19,962 Added 2.27%	897,954 $61.5 Million
Q1 2024 May 14, 2024	SELL	$64.37 - $75.65 $2.98 Million - $3.5 Million	-46,223 Reduced 5.0%	877,992 $60.8 Million
Q4 2023 Feb 13, 2024	SELL	$46.37 - $73.65 $1.14 Million - $1.81 Million	-24,583 Reduced 2.59%	924,215 $66.2 Million
Q3 2023 Nov 13, 2023	BUY	$52.09 - $64.1 $589,137 - $724,970	11,310 Added 1.21%	948,798 $49.4 Million
Q2 2023 Aug 11, 2023	BUY	$54.67 - $66.44 $1.09 Million - $1.33 Million	20,010 Added 2.18%	937,488 $59.4 Million
Q1 2023 May 15, 2023	SELL	$43.8 - $56.99 $713,195 - $927,968	-16,283 Reduced 1.74%	917,478 $49.7 Million
Q4 2022 Feb 13, 2023	BUY	$44.07 - $54.45 $110,086 - $136,016	2,498 Added 0.27%	933,761 $49.4 Million
Q3 2022 Nov 14, 2022	SELL	$42.7 - $59.99 $183,994 - $258,496	-4,309 Reduced 0.46%	931,263 $43.3 Million
Q2 2022 Aug 12, 2022	BUY	$43.0 - $65.64 $2.65 Million - $4.04 Million	61,594 Added 7.05%	935,572 $53.4 Million
Q1 2022 May 13, 2022	BUY	$38.74 - $62.09 $2.38 Million - $3.81 Million	61,392 Added 7.56%	873,978 $53.5 Million
Q4 2021 Feb 08, 2022	SELL	$35.2 - $53.42 $570,627 - $865,991	-16,211 Reduced 1.96%	812,586 $42.5 Million
Q3 2021 Nov 15, 2021	SELL	$28.72 - $42.49 $828,945 - $1.23 Million	-28,863 Reduced 3.37%	828,797 $30.9 Million
Q2 2021 Aug 13, 2021	BUY	$29.3 - $44.5 $964,321 - $1.46 Million	32,912 Added 3.99%	857,660 $35 Million
Q1 2021 May 12, 2021	SELL	$30.8 - $39.51 $4 Million - $5.13 Million	-129,803 Reduced 13.6%	824,748 $28 Million
Q4 2020 Feb 11, 2021	SELL	$23.34 - $32.22 $374,933 - $517,582	-16,064 Reduced 1.66%	954,551 $30.4 Million
Q3 2020 Nov 16, 2020	BUY	$17.61 - $31.86 $1.48 Million - $2.68 Million	84,097 Added 9.49%	970,615 $24.9 Million
Q2 2020 Aug 14, 2020	BUY	$14.35 - $26.64 $3 Million - $5.57 Million	209,045 Added 30.86%	886,518 $22.8 Million
Q1 2020 May 14, 2020	BUY	$12.31 - $33.12 $1.32 Million - $3.55 Million	107,125 Added 18.78%	677,473 $10.4 Million
Q4 2019 Feb 14, 2020	SELL	$7.26 - $38.49 $129,438 - $686,238	-17,829 Reduced 3.03%	570,348 $19.6 Million
Q3 2019 Nov 13, 2019	BUY	$7.47 - $14.03 $205,992 - $386,891	27,576 Added 4.92%	588,177 $4.39 Million
Q2 2019 Aug 13, 2019	BUY	$10.65 - $14.29 $91,206 - $122,379	8,564 Added 1.55%	560,601 $7.28 Million
Q1 2019 May 13, 2019	BUY	$10.9 - $14.09 $38,477 - $49,737	3,530 Added 0.64%	552,037 $6.73 Million
Q4 2018 Feb 12, 2019	SELL	$10.36 - $20.96 $55,653 - $112,597	-5,372 Reduced 0.97%	548,507 $6.25 Million
Q3 2018 Nov 14, 2018	BUY	$17.77 - $22.9 $246,345 - $317,462	13,863 Added 2.57%	553,879 $12 Million
Q2 2018 Sep 18, 2018	SELL	$17.33 - $23.4 $61,885 - $83,561	-3,571 Reduced 0.66%	540,016 $9.54 Million
Q2 2018 Aug 14, 2018	BUY	$17.33 - $23.4 $866,915 - $1.17 Million	50,024 Added 10.14%	543,587 $9.61 Million
Q1 2018 May 09, 2018	BUY	$15.16 - $25.49 $115,185 - $193,673	7,598 Added 1.56%	493,563 $10.4 Million
Q4 2017 Feb 14, 2018	BUY	$14.27 - $16.79 $1.17 Million - $1.38 Million	82,140 Added 20.34%	485,965 $7.04 Million
Q3 2017 Nov 13, 2017	BUY	$10.77 - $22.1 $4.35 Million - $8.92 Million	403,825	403,825 $6.37 Million

Others Institutions Holding ITCI

# of Institutions

400

Shares Held

87.2M

Call Options Held

309K

Put Options Held

302K

View Full List

About Intra-Cellular Therapies, Inc.

Ticker ITCI
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 94,401,696
Market Cap $6.92B
Description
Intra-Cellular Therapies, Inc., a biopharmaceutical company, develops novel drugs for the treatment of neuropsychiatric and neurologic diseases by targeting intracellular signaling mechanisms within the central nervous system in the United States. The company offers CAPLYTA for the treatment of schizophrenia in adults. It is also involved in dev...

More about ITCI

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Northern Trust Corp, based on Form 13F filings with the SEC.

News

Stay updated on Northern Trust Corp with notifications on news.

Account

Northern Trust Corp Intra Cellular Therapies, Inc. Transaction History